Levothyroxine compositions having unique Cmax properties
First Claim
Patent Images
1. An immediate release pharmaceutical composition comprising a levothyroxine salt, wherein the composition exhibits a levothyroxine (T4) plasma Cmax of between from about 10 μ
- g/dl to about 20 μ
g/dl as determined by a standard Cmax test.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
-
Citations
4 Claims
-
1. An immediate release pharmaceutical composition comprising a levothyroxine salt, wherein the composition exhibits a levothyroxine (T4) plasma Cmax of between from about 10 μ
- g/dl to about 20 μ
g/dl as determined by a standard Cmax test. - View Dependent Claims (2, 3, 4)
- g/dl to about 20 μ
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeElaine A. Strauss, Franz G. Andrew, Phillip A. Dimenna, Rocco L. Gemma
-
Original AssigneeElaine A. Strauss, Franz G. Andrew, Phillip A. Dimenna, Rocco L. Gemma
-
InventorsGemma, Rocco L., Franz, G. Andrew, Strauss, Elaine A., DiMenna, Phillip A.
-
Application NumberUS10/218,951Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/567CPC Class CodesA61K 31/198 Alpha-amino acids, e.g. ala...
